Novo Nordisk shares plunge 19% after disappointing trial results; Lilly jumps in premarket - CNBC
- Novo Nordisk shares plunge 19% after disappointing trial results; Lilly jumps in premarket CNBC
- Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it CNN
- Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump. Investor's Business Daily
- Novo Nordisk Falls Most on Record After New Weight Drug Disappoints Bloomberg